Bristol-Myers Squibb Company (BMY) Stock Price, Quote & News

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unres...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 609 252 4621

Website: www.bms.com

Address:

Route 206 & Province Line Road, Princeton, United States

PhantomZ Jun. 10 at 9:14 PM

$TLTFF $MRK $PFE $BMY https://medicalxpress.com/news/2026-06-ultrasound-anticancer-molecule-deep-lung.html

0 · Reply

Fingerlickengood Jun. 10 at 4:17 PM

$CDXS $MRK $ALNY $BMY I believe the importance of this during their 2026 USA TIDES presentation was completely overlooked by focusing on 'stereo chemistry'. While the 'stereochemistry' aspect is important, this capability sets the EcoSynthesis Platform WELL AHEAD of any other existing and competing technologies! This alone will make it king, and the industry standard! https://www.codexis.com/technical-content/controlling-stereochemistry/

0 · Reply

Woodman7 Jun. 10 at 1:15 PM

$BMY $JNJ $ABT $PFIZER.NSE Check this Clene news

0 · Reply

Quantumup Jun. 9 at 7:06 PM

Raymond James says that w/ unanimous board approval, it sees no reason the $NUVL and $GSK M&A deal would not close in a timely manner—it thinks GSK is paying a fair price. ⬇️Nuvalent to Market Perform from Outperform $NUVB $BMY

0 · Reply

Quantumup Jun. 9 at 5:41 PM

RBC Capital sees pot'l readthrough to $NUVB (Outperform; $20) after $NUVL - $GSK M&A deal. $BMY Here's what RBC Capital had to say in its note to investors: https://x.com/Quantumup1/status/2064401843447276017?s=20

0 · Reply

taxplanr Jun. 9 at 12:33 PM

$BNTX $MRNA $MRK $BMY do you know why RNA programming will never work even for cancer? https://www.instagram.com/reel/DZLfm1EybwI/?igsh=b2ZiaG9vOGs5MXd0

1 · Reply

STOCKPICKERTRADER Jun. 8 at 7:11 PM

$PFE continues to make steady progress on a number of fronts as product lines expand and grow. Position into on weakness imho. Sector still weak and many big names performing poorly today $BMY $REGN $AMGN $BIIB for a few, but number of undervalued big names with solid dividends to boot!

1 · Reply

focafoca99 Jun. 8 at 11:32 AM

$BMY introduced its new multiple myeloma awareness campaign with Mariska Hargitay. https://www.rapidticker.com/news/bmy-mariska-hargitay-partners-with-bristol-ed2008

0 · Reply

CaesarZane Jun. 7 at 9:13 PM

$GOOG $BMY $XOM 🚀🚀🚀 https://youtu.be/uk632v0svsY

0 · Reply

OnlyFibs Jun. 6 at 5:36 PM

$BMY is executing a masterful pipeline pivot. While the Street is stuck in "patent cliff" rearview-mirror thinking, the ASCO 2026 data shows mezigdomide is an absolute beast in multiple myeloma (52% progression risk reduction!). This isn't a legacy play anymore; it's a focused oncology innovator building high-margin durability. 🔬 🐂 Bull Level: Reclaim $57.00 to confirm the breakout toward $60.00+. 🐻 Bear Level: $54.00 is the non-negotiable floor. #BMY #BristolMyers #Oncology #Biotech #hovdid

1 · Reply

Bristol-Myers Squibb Company Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 3:20 AM EDT - 1 day ago

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

LLY MRK PFE RDW UTHR XBI

Jun 8, 2026, 6:59 AM EDT - 2 days ago

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

2026-06-03T13:40:17.000Z - 7 days ago

Arcus enters clinical trial collaboration, supply agreement with Bristol Myers

RCUS

Jun 3, 2026, 8:00 AM EDT - 7 days ago

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer

RCUS

2026-06-02T13:36:01.000Z - 8 days ago

Bristol Myers, SystImmune announce results from analyses of iza-bren studies

Jun 2, 2026, 8:00 AM EDT - 8 days ago

Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma

2026-06-01T11:16:45.000Z - 9 days ago

Bristol Myers: Opdivo in combination with AVD receives expanded EU label

2026-06-01T11:15:21.000Z - 9 days ago

Bristol Myers says FDA accepts sNDA for Camzyos

Jun 1, 2026, 6:59 AM EDT - 9 days ago

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Jun 1, 2026, 6:55 AM EDT - 9 days ago

Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma

2026-05-31T21:45:07.000Z - 10 days ago

BioNTech, Bristol announce interim Phase 2 data from Rosetta Lung-02 trial

BNTX

2026-05-29T15:51:38.000Z - 12 days ago

C4 Therapeutics jumps after Bristol Myers myeloma data

CCCC

2026-05-29T13:14:13.000Z - 12 days ago

Bristol Myers says CELMoD mezigdomide reduces risk of disease progression by 52%

May 29, 2026, 8:02 AM EDT - 12 days ago

Bristol Myers drug delays myeloma progression in hard to treat patients

$Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma$

May 29, 2026, 8:00 AM EDT - 12 days ago

Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma

May 27, 2026, 6:59 AM EDT - 14 days ago

Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

May 21, 2026, 5:01 PM EDT - 20 days ago

Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline

2026-05-20T13:28:21.000Z - 21 days ago

BMY Stock Rises as Bristol Myers Brings Anthropic’s Claude AI to 30,000 Employees

LLY NVDA

May 20, 2026, 7:49 AM EDT - 21 days ago

Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery

2026-05-20T11:00:11.000Z - 21 days ago

Bristol Myers announces strategic agreement with Anthropic

May 20, 2026, 6:59 AM EDT - 21 days ago

Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations

May 20, 2026, 6:45 AM EDT - 21 days ago

Bristol-Myers Squibb Brings Anthropic's Claude to 30,000 of Its Staff

May 18, 2026, 9:44 AM EDT - 23 days ago

US Supreme Court rebuffs pharma challenge to Biden-era drug price

AZN NVO NVS

May 15, 2026, 11:04 AM EDT - 26 days ago

Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaboration

May 14, 2026, 11:40 AM EDT - 27 days ago

Bristol-Myers Squibb Company Transcript: Bank of America Global Healthcare Conference 2026

2026-05-14T15:30:17.000Z - 27 days ago

Tempus AI announces strategic collaboration with Bristol Myers

TEM

May 14, 2026, 8:30 AM EDT - 27 days ago

Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience

TEM

May 12, 2026, 4:01 PM EDT - 4 weeks ago

Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees

PCRX

May 12, 2026, 2:35 AM EDT - 4 weeks ago

Bristol-Myers Squibb and China's Hengrui Pharma Forge Tie-Up

May 12, 2026, 12:27 AM EDT - 4 weeks ago

Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology

May 12, 2026, 12:19 AM EDT - 4 weeks ago

China's Jiangsu Hengrui, Bristol Myers Squibb in deal worth up to $15.2 bln

May 8, 2026, 6:59 AM EDT - 4 weeks ago

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults

May 6, 2026, 6:59 AM EDT - 5 weeks ago

Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026

May 5, 2026, 10:00 AM EDT - 5 weeks ago

Bristol-Myers Squibb Company Transcript: AGM 2026

May 4, 2026, 6:59 AM EDT - 5 weeks ago

Bristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026™

May 1, 2026, 10:03 AM EDT - 5 weeks ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

ABBV GILD GSK LLY

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Bristol-Myers Squibb Company Earnings Call Transcript: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Bristol-Myers Squibb Company Earnings release: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Bristol-Myers Squibb Company Slides: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Bristol-Myers Squibb Company Quarterly report: Q1 2026

Apr 30, 2026, 7:11 AM EDT - 5 weeks ago

Bristol Myers Squibb Logs Higher Sales, Profit

Apr 30, 2026, 7:01 AM EDT - 5 weeks ago

Bristol Myers posts higher-than-expected quarterly profit on blood thinner, cancer sales

Apr 30, 2026, 6:59 AM EDT - 5 weeks ago

Bristol Myers Squibb Reports First Quarter Financial Results for 2026

Apr 24, 2026, 8:36 AM EDT - 6 weeks ago

Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban's online pharmacy

PFE

Apr 24, 2026, 6:59 AM EDT - 6 weeks ago

Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company

Apr 23, 2026, 8:00 AM EDT - 6 weeks ago

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

RNA

Apr 21, 2026, 7:00 AM EDT - 7 weeks ago

Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP Deletion

Apr 20, 2026, 8:00 AM EDT - 7 weeks ago

Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer

ARDX

Apr 17, 2026, 8:00 AM EDT - 7 weeks ago

Bristol-Myers Squibb Company Proxy statement: Proxy filing

Apr 15, 2026, 7:00 AM EDT - 2 months ago

Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

Apr 9, 2026, 7:00 AM EDT - 2 months ago

Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours

Apr 7, 2026, 2:54 PM EDT - 2 months ago

15 stocks to put on your list to buy when the market recovers

ADBE CVS KNSL MS NVDA TGT USB

Apr 3, 2026, 11:08 AM EDT - 2 months ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

ABBV AMGN AZN MRK NVO

Apr 2, 2026, 5:34 PM EDT - 2 months ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

AZN NVO ABBV AMGN MRK

Apr 2, 2026, 5:33 PM EDT - 2 months ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

ABBV AMGN AZN MRK NVO

Apr 2, 2026, 3:29 PM EDT - 2 months ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

AZN NVO ABBV AMGN MRK

Apr 2, 2026, 2:59 PM EDT - 2 months ago

Global pharma companies that have publicly announced Trump drug pricing agreements

ABBV AMGN AZN MRK

Mar 31, 2026, 6:59 AM EDT - 2 months ago

Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years

Mar 29, 2026, 11:45 AM EDT - 2 months ago

Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Mar 28, 2026, 7:00 AM EDT - 2 months ago

Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)

Mar 25, 2026, 8:00 AM EDT - 2 months ago

Bristol-Myers Squibb Company Proxy statement: Proxy filing

Mar 25, 2026, 8:00 AM EDT - 2 months ago

Bristol-Myers Squibb Company Proxy statement: Proxy filing

Mar 23, 2026, 6:59 AM EDT - 2 months ago

Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)

Mar 20, 2026, 4:42 PM EDT - 2 months ago

Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)

Mar 20, 2026, 12:23 PM EDT - 2 months ago

US FDA approves Bristol Myers Squibb's cancer drug for Hodgkin's lymphoma

Mar 19, 2026, 6:59 AM EDT - 2 months ago

Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026

Mar 18, 2026, 2:23 PM EDT - 3 months ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN GILD GSK JNJ LLY

$Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma$

Mar 9, 2026, 6:59 AM EDT - 3 months ago

Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

Mar 6, 2026, 9:59 PM EST - 3 months ago

U.S. FDA Approves Bristol Myers Squibb's Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis

PhantomZ Jun. 10 at 9:14 PM

$TLTFF $MRK $PFE $BMY https://medicalxpress.com/news/2026-06-ultrasound-anticancer-molecule-deep-lung.html

0 · Reply

Fingerlickengood Jun. 10 at 4:17 PM

0 · Reply

Woodman7 Jun. 10 at 1:15 PM

$BMY $JNJ $ABT $PFIZER.NSE Check this Clene news

0 · Reply

Quantumup Jun. 9 at 7:06 PM

0 · Reply

Quantumup Jun. 9 at 5:41 PM

0 · Reply

taxplanr Jun. 9 at 12:33 PM

$BNTX $MRNA $MRK $BMY do you know why RNA programming will never work even for cancer? https://www.instagram.com/reel/DZLfm1EybwI/?igsh=b2ZiaG9vOGs5MXd0

1 · Reply

STOCKPICKERTRADER Jun. 8 at 7:11 PM

1 · Reply

focafoca99 Jun. 8 at 11:32 AM

$BMY introduced its new multiple myeloma awareness campaign with Mariska Hargitay. https://www.rapidticker.com/news/bmy-mariska-hargitay-partners-with-bristol-ed2008

0 · Reply

CaesarZane Jun. 7 at 9:13 PM

$GOOG $BMY $XOM 🚀🚀🚀 https://youtu.be/uk632v0svsY

0 · Reply

OnlyFibs Jun. 6 at 5:36 PM

1 · Reply

SellasgpsCurativeBAT11 Jun. 5 at 5:57 PM

$BMY $PFE $SLS All the Big 5 Pharmaceuticals are green. Money rotation in to Pharmaceuticals bodes well for Sellas BO. ✌️🙏❤️‍🩹

0 · Reply

55X_ROI_Q1_2026 Jun. 5 at 5:45 PM

$SLS $PFE $BMY too

0 · Reply

tony93 Jun. 5 at 2:51 PM

$BMY wants 58

0 · Reply

truehealthvalue Jun. 5 at 9:39 AM

$BMY I would look at $ELTX, About to take off, it will be worth billions in a short time

0 · Reply

biolover Jun. 5 at 6:07 AM

$VKTX CEO confirmed high awareness of their obesity program across industry and high interest by BP .. essentially what we have been hearing from the likes of $ABBV $AMGN $NVO $BMY and likely others. Also his expectation for low GI issues with maintenance dosing in trial . Early cohort on this trial entered in Oct - Nov time line so good portion would have been already on monthly or q 2 wk dosing by now. Small trial and CEO should get timely reporting. This CEO has a history of giving clues as he hinted about higher GI issues with oral phase 2 ( turned out due to 4 large pills for 120 mg ) wks prior to reporting. Now he is upbeat on maintenance tolerability. Sounds like at least no vomit issue with first 21 wks despite more rapid escalation vs phase 3. ( I know there is no vomit issue with the vanquish program at more than one site as posted earlier ) I think all the slight delay with amylin likely to get oral amylin going. Based on his previous statements.

0 · Reply

ApexEquityVault Jun. 4 at 2:18 PM

$BMY 05 JUN 26 $58 CALL $0.15 CLINICAL TRIAL COLLAB + INSIDE BAR + RELATIVE STRENGTH + SECTOR HOT

0 · Reply

Blockwave1 Jun. 4 at 2:17 PM

$BMY 🚨 05 JUN 26 $58 CALL $0.15 CLINICAL TRIAL COLLAB + INSIDE BAR + RELATIVE STRENGTH + SECTOR HOT

0 · Reply

Quantumup Jun. 4 at 12:03 PM

Citizens on $KURA: We reiterate our Market Outperform rating on Kura Oncology and price target of $24, based on a blended discounted EPS and revenue multiple analysis. $BMY SNDX AMGN ABBV - RHHBY $RVMD Here's what Citizens additionally said: https://x.com/Quantumup1/status/2062504701707370657?s=20

0 · Reply

Prady Jun. 3 at 10:31 PM

$BMY 70 soon

0 · Reply

Mitchell22 Jun. 3 at 6:40 PM

$BMY Bristol Myers Squibb (BMS) offers medication savings through co-pay assistance for commercially insured patients and free medication programs for eligible uninsured or underinsured patients. Key options include BMS Access Support (1-800-861-0048) for co-pay cards and BMSPAF (1-800-736-0003) for the independent charitable foundation.

0 · Reply

TeresaTrades Jun. 3 at 1:32 PM

Largest CALL OI Increases $NU $DVN $INTC $BMY $ET

0 · Reply

Market Cap	113.48B
Revenue (ttm)	48.19B
Net Income (ttm)	7.05B
EPS (ttm)	N/A
PE Ratio	9.66
Forward PE	9.06
Profit Margin	14.64%
Debt to Equity Ratio	2.21

Volume	8,132,776
Avg Vol	10,812,666
Day's Range	N/A - N/A
Shares Out	2.04B
Stochastic %K	63%
Beta	0.24
Analysts	Sell
Price Target	$62.88